반응식
[CH3:1][C:2]1[CH:3]=[CH:4][C:5]([C:12]2C=N[N:15]([CH3:17])[CH:16]=2)=[C:6]([CH:11]=1)[C:7]([O:9][CH3:10])=[O:8].CC1C=CC(B2OC(C)(C)C(C)(C)O2)=C(C=1)C(OC)=O.I[C:39]1C=NC=C[N:40]=1>>[CH3:1][C:2]1[CH:3]=[CH:4][C:5]([C:12]2[CH:16]=[N:15][CH:17]=[CH:39][N:40]=2)=[C:6]([CH:11]=1)[C:7]([O:9][CH3:10])=[O:8]참가 물질
4
실험 절차
The title compound was synthesized following the same general protocol as described for methyl 5-methyl-2-(1-methyl-1H-pyrazol-4-yl)benzoate in Example A1, using methyl 5-methyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate and using 2-iodopyrazine. ESI-MS (m/z): 229 [M+1]+.
출처 및 근거
- ORD 기록
- ord-49df807a707541b29b8c7e7fd0c9622e
- 출처 데이터셋
- uspto-grants-2016_09
- 특허 번호
- US09440982B2
연결된 노트
불러오는 중…